Description

Nimotuzumab CAS NO 780758-10-3 is a humanized monoclonal antibody designed to target and inhibit the epidermal growth factor receptor (EGFR). This targeted therapeutic agent is significant for its role in modulating cell proliferation and survival pathways implicated in various oncological conditions. It is primarily required by pharmaceutical manufacturers, biotechnology research institutions, and clinical development organizations engaged in advanced cancer therapy and immunology research.

Application

• Primary therapeutic agent for the treatment of head and neck squamous cell carcinoma (HNSCC).
• Clinical research and development for EGFR-positive tumors, including glioma and nasopharyngeal carcinoma.
• Use in combination therapy regimens to enhance the efficacy of radiotherapy and chemotherapy.
• Key biological reagent in preclinical studies for investigating EGFR signaling pathways and tumor biology.
• Manufacturing of biosimilar or biobetter versions for global oncology markets.
• Component in diagnostic assay development for detecting EGFR expression levels in tumor samples.

Basic Information

Product Name	Nimotuzumab
CAS No.	780758-10-3
Molecular Formula	C6440H9916N1704O2016S46
Molecular Weight	Approx. 145 kDa
Synonyms	h-R3; TheraCIM; BIOMAb EGFR; Anti-EGFR Monoclonal Antibody h-R3; Humanized Anti-EGFR mAb; EGFR Inhibitor h-R3; Theraloc; YMB-1000; Nimotuzumab (USAN/INN)
EINECS	Contact for details

Quality Control

Our Nimotuzumab is manufactured under strict quality systems compliant with current Good Manufacturing Practices (cGMP) for biopharmaceuticals. Each batch undergoes comprehensive analytical testing including potency, purity, identity, and safety assays. Certificates of Analysis (COA) detailing specifications for appearance, protein concentration, biological activity (e.g., EGFR binding affinity), purity by SEC-HPLC, host cell proteins, endotoxin levels, and sterility are available upon request.

Storage

Preserve in a tightly closed container, protected from light. For long-term stability, store lyophilized powder at 2-8°C. Reconstituted or liquid formulations should be handled aseptically and stored according to the specific product datasheet, typically at 2-8°C for a limited duration. This product is hygroscopic (moisture-sensitive).

Specification

Item	Specification
Appearance	White to off-white lyophilized powder or clear to slightly opalescent solution
Identification (SEC-HPLC / Binding Assay)	Conforms to reference standard
Protein Content	≥ 95.0%
Purity (SEC-HPLC)	Monomer ≥ 98.0%
Potency (Cell-based ELISA / SPR)	90% - 110% of reference
pH	6.5 - 7.5 (for solution)
Endotoxin	< 1.0 EU/mg
Sterility	Sterile (complying with Ph. Eur. 2.6.1 / USP <71>)

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.